The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
β-Blocker Therapy in Heart Failure: Scientific Review
Abstract
CONTEXT: Care of patients with heart failure has been revolutionized throughout the past decade. A paradigm shift in the strategy for treating heart failure caused by systolic dysfunction is in progress. Despite the initial perception about beta-blockers' safety, they are now the most extensively studied class of agents in the treatment of heart failure and have emerged as an important intervention to improve the clinical outcomes of heart failure patients. OBJECTIVE: To provide scientific rationale for the use of beta-blockers for patients with heart failure. DATA SOURCES: All English-language articles of large, randomized controlled clinical trials assessing the mortality benefits of beta-blockers in patients with heart failure were identified to provide the scientific rationale for the use of beta-blockers in heart failure. Basic science studies were reviewed to provide an overview of the potential physiologic role of beta-blockers in heart failure. Finally, clinical guidelines for the treatment of patients with heart failure were assessed to determine current recommendations for the use of these agents. STUDY SELECTION AND DATA EXTRACTION: Randomized controlled clinical trials of beta-blockers that included more than 300 subjects and assessed mortality as a primary end point. DATA SYNTHESIS: Of the 4 beta-blockers tested in large randomized controlled clinical trials of patients with heart failure, 3 are available in the United States, bisoprolol, carvedilol, and metoprolol; 2 of these, carvedilol and metoprolol, have Food and Drug Administration indications for the treatment of heart failure. Compared with placebo treatment, beta-blocker use is associated with a consistent 30% reduction in mortality and a 40% reduction in hospitalizations in patients with class II and III heart failure. CONCLUSIONS: Tested in more than 10,000 patients, beta-blockers reduce morbidity and mortality in class II through IV heart failure. Along with angiotensin-converting enzyme inhibitors, digoxin, and diuretics, beta-blockers have strengthened the armamentarium to improve clinical outcomes of heart failure patients. The science supporting beta-blockers must be translated into practice safely and rationally if the agents are to achieve their full potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
Packer, M., Bristow, M. R., Cohn, J. N., Colucci, W. S., Fowler, M. B., Gilbert, E. M., & Shusterman, N. H. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605233342101 · Cited by 4,649
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
Cohn, J. N., Levine, T. B., Olivari, M. T., Garberg, V., Lura, D., Francis, G. S., Simon, A. B., & Rector, T. (1984) · New England Journal of Medicine · doi:10.1056/nejm198409273111303 · Cited by 3,125
Effect of carvedilol on survival in severe chronic heart failure
Packer, M., Coats, A. J. S., & Fowler, M. B. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(01)00477-9 · Cited by 1,661
Guidelines for the diagnosis and treatment of chronic heart failure
Remme, W. (2001) · European Heart Journal · doi:10.1053/euhj.2001.2783 · Cited by 1,592
Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA · doi:10.1001/jama.283.10.1295 · Cited by 1,399
Francis, G. S., Benedict, C., Johnstone, D. E., Kirlin, P. C., Nicklas, J., Liang, C. S., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,388
Bristow, M. R., Gilbert, E. M., Abraham, W. T., Adams, K. F., Fowler, M. B., Hershberger, R. E., Kubo, S. H., Narahara, K. A., Ingersoll, H., Krueger, S., et al. (1996) · Circulation · doi:10.1161/01.cir.94.11.2807 · Cited by 1,303
Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
Waagstein, F., Hjalmarson, A., Swedberg, K., Bristow, M. R., Gilbert, E. M., Camerini, F., Fowler, M. B., Silver, M. A., Johnson, M. R., & Goss, F. G. (1993) · The Lancet · doi:10.1016/0140-6736(93)92930-r · Cited by 1,234
A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart Failure
(2001) · New England Journal of Medicine · doi:10.1056/nejm200105313442202 · Cited by 1,007
Cited by
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Diretrizes Brasileiras de Hipertensão Arterial – 2020
Barroso, W. K. S., Rodrigues, C. I. S., Bortolotto, L. A., Mota-Gomes, M. A., Brandão, A. A., Feitosa, A. D. D. M., Machado, C. A., Poli-de-Figueiredo, C. E., Amodeo, C., Mion, D., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20201238 · Cited by 1,068
van Kimmenade, R. R., Januzzi, J. L., Ellinor, P. T., Sharma, U. C., Bakker, J. A., Low, A. F., Martinez, A., Crijns, H. J., MacRae, C. A., Menheere, P. P., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.061 · Cited by 567
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
McAlister, F. A., Wiebe, N., Ezekowitz, J. A., Leung, A. A., & Armstrong, P. W. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00006 · Cited by 479
Smart, N., & Marwick, T. H. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.11.033 · Cited by 414
Roccaforte, R., Demers, C., Baldassarre, F., K. Teo, K., & Yusuf, S. (2005) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.08.005 · Cited by 342
Common risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 314
Barker, W. H., Mullooly, J. P., & Getchell, W. (2006) · Circulation · doi:10.1161/circulationaha.104.492033 · Cited by 260
Carvedilol and its new analogs suppress arrhythmogenic store overload–induced Ca2+ release
Zhou, Q., Xiao, J., Jiang, D., Wang, R., Vembaiyan, K., Wang, A., Smith, C. D., Xie, C., Chen, W., Zhang, J., et al. (2011) · Nature Medicine · doi:10.1038/nm.2406 · Cited by 255
Torp-Pedersen, C., Metra, M., Charlesworth, A., Spark, P., Lukas, M. A., Poole-Wilson, P. A., Swedberg, K., Cleland, J. G. F., Di Lenarda, A., Remme, W. J., et al. (2007) · Heart · doi:10.1136/hrt.2006.092379 · Cited by 171
Cardiac and neuroprotection regulated by α1-adrenergic receptor subtypes
Perez, D. M., & Doze, V. A. (2011) · Journal of Receptors and Signal Transduction · doi:10.3109/10799893.2010.550008 · Cited by 59
Beta‐blockers may reduce intrusive thoughts in newly diagnosed cancer patients
Lindgren, M. E., Fagundes, C. P., Alfano, C. M., Povoski, S. P., Agnese, D. M., Arnold, M. W., Farrar, W. B., Yee, L. D., Carson, W. E., Schmidt, C. R., et al. (2013) · Psycho-Oncology · doi:10.1002/pon.3233 · Cited by 35
Metadata
- Authors
- Foody, J. M., Farrell, M. H., & Krumholz, H. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-02-20
- Volume
- 287
- Issue
- 7
- Pages
- 883
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2172146634
- Cited by
- 322
- References
- 52
- FWCI
- 14.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.